| Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
| |
| Device | PD-L1 IHC 28-8 pharmDx |
| Applicant | Agilent Technologies, Inc. 5301 Stevens Creek Blvd. Santa Clara, CA 95051 |
| PMA Number | P150025 |
| Date Received | 07/09/2015 |
| Decision Date | 10/09/2015 |
| Docket Number | 15M-4016 |
| Notice Date | 11/02/2015 |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT01673867
|
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement APPROVAL FOR THE PD-L1 IHC 28-8 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING:1) PD-L1 IHC 28-8 PHARMDX IS A QUALITATIVE IMMUNOHISTO-CHEMICAL ASSAY USING MONOCLONAL RABBIT ANTI-PD-L1, CLONE 28-8 INTENDED FOR USE IN THE DETECTION OF PD-L1 PROTEIN IN FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48; 2) PD-L1 PROTEIN EXPRESSION IS DEFINED AS THE PERCENTAGE OF TUMOR CELLS EXHIBITING POSITIVE MEMBRANE STAINING AT ANY INTENSITY; AND3) PD-L1 EXPRESSION AS DETECTED BY PD-L1 IHC 28-8 PHARMDX IN NON-SQUAMOUS NSCLC MAY BE ASSOCIATED WITH ENHANCED SURVIVAL FROM OPDIVO (NIVOLUMAB). |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling
|
| Supplements: |
S001 S006 S003 S004 S005 S002 S013 S011 S014 S017 S016 S018 S009 S008 S010 S015 S019 S020 |
|
|